ALXO — Alx Oncology Holdings

Alx Oncology Holdings (ALXO) is a biotechnology company listed on NASDAQ. It is led by Jason W. Lettmann, based in 323 Allerton Avenue, South San Francisco, CA, United States, 94080, with about 43 employees. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Net income was -$78.8M. ALXO currently screens at market cap $207.2M.

Use this ALXO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ALXO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ALXO SEC filings page. Lician reads the product cache first so this HTML stays unique to Alx Oncology Holdings even when a live quote feed is slow.